当前位置: 首页 > 详情页

Inhibition of activator protein 1 attenuates neuroinflammation and brain injury after experimental intracerebral hemorrhage

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China [2]Center for Neuroinflammation, Beijing Tiantan Hospital, Capital Medical University, Beijing, China [3]Department of Neurology, Tianjin Huanhu Hospital, Tianjin, China [4]Center for Neurological Diseases, The Third People's Hospital of Datong, Datong, China
出处:
ISSN:

关键词: activator protein 1 brain injury intracerebral hemorrhage microglia neuroinflammation

摘要:
Aims: Intracerebral hemorrhage (ICH) is a devastating type of stroke without specific treatment. Activator protein 1 (AP-1), as a gene regulator, initiates cytokine expression in response to environmental stimuli. In this study, we investigated the relationship between AP-1 and neuroinflammation-associated brain injury triggered by ICH. Methods: Intracerebral hemorrhage mice were developed by autologous blood or collagenase infusion. We measured the dynamics of AP-1 in mouse brain tissues during neuroinflammation formation after ICH. The effects of the AP-1 inhibitor SR11302 on brain injury and neuroinflammation as well as the underlying mechanisms were investigated in vivo and in vitro. Results: AP-1 was significantly upregulated in mouse brain tissue as early as 6 hours after ICH, accompanied by elevations in proinflammatory factors, including interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF)-α. Inhibition of AP-1 using SR11302 reduced neurodeficits and brain edema at day 3 after ICH. SR11302 ablated microglial IL-6 and TNF-α production and brain-infiltrating leukocytes in ICH mice. In addition, SR11302 treatment diminished thrombin-induced production of IL-6 and TNF-α in cultured microglia. Conclusions: Inhibition of AP-1 curbs neuroinflammation and reduces brain injury following ICH. © 2019 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 2 区 医学
小类 | 2 区 药学 3 区 神经科学
最新[2023]版:
大类 | 1 区 医学
小类 | 2 区 神经科学 2 区 药学
JCR分区:
出版当年[2017]版:
Q1 PHARMACOLOGY & PHARMACY Q2 NEUROSCIENCES
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q1 NEUROSCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China [2]Center for Neuroinflammation, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
通讯作者:
通讯机构: [1]Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China [4]Center for Neurological Diseases, The Third People's Hospital of Datong, Datong, China [*1]Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin 300052, China [*2]Center for Neurological Diseases, The Third People's Hospital of Datong, Datong, Shanxi 037008, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16461 今日访问量:0 总访问量:871 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院